Volume 22, Issue 134 (8-2015)                   RJMS 2015, 22(134): 41-48 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Survival analysis of acute myeloid leukemia. RJMS 2015; 22 (134) :41-48
URL: http://rjms.iums.ac.ir/article-1-3921-en.html
Abstract:   (33309 Views)

Background: Blood cancer (leukemia) is the cancer of blood tissue and Acute Myeloid Leukemia (AML) is the third most prevalent type in Iran. Survival time after diagnosis and its risk factors are one of the most important indicators for assessing the treatment.

Methods: Data for this prospective study belong to Valiasr 2 (Imam Khomeini Hospital) AML patients during 2008-2013. A total of 85 patients were enrolled and death time was considered as failure event for them. Kaplan-Meier method and Cox proportional hazard model were used to identify the risk factors of patient’s survival. The SPSS v.21 and SAS v. 9.2 were used for analysis of data and &alpha=0.05 was considered as significant level.

Results: Of 85 patients, 46 (54.1%) were male. The mean age at diagnosis time was 41.38 yr., and median survival time was 17.27, and 53 patients died. Age at diagnosis, marital status, smoking, bone marrow transplants, disease history, region, lodging and resistance to treatment, and some laboratory factors (such as the number of white blood cells and red blood cells, mean corpuscular hemoglobin, sodium, potassium and calcium) were significant on survival time of patients.

Conclusion: Because of the importance of leukemia, especially the role of AML type in mortality, an emphasis on age at diagnosis, marital status, smoking, bone marrow transplant, disease history, region and resistance to treatment and some laboratory factors are very important in the prognosis of death in patients.

Full-Text [PDF 2451 kb]   (8330 Downloads)    
Type of Study: Research | Subject: Hematology & oncology

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Razi Journal of Medical Sciences

Designed & Developed by : Yektaweb